Attached files
file | filename |
---|---|
EX-23.1 - EX-23.1 - Generation Bio Co. | d941845dex231.htm |
EX-5.1 - EX-5.1 - Generation Bio Co. | d941845dex51.htm |
As filed with the Securities and Exchange Commission on June 11, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
GENERATION BIO CO.
(Exact name of registrant as specified in its charter)
Delaware | 2834 | 81-4301284 | ||
(State or other jurisdiction of incorporation or organization) |
(Primary Standard Industrial Classification Code Number) |
(I.R.S. Employer Identification No.) |
301 Binney Street
Cambridge, MA 02142
(617) 655-7500
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Geoff McDonough, M.D.
President and Chief Executive Officer
Generation Bio Co.
301 Binney Street
Cambridge, MA 02142
(617) 655-7500
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
Stuart M. Falber, Esq. Molly W. Fox, Esq. Wilmer Cutler Pickering Hale and Dorr LLP 60 State Street Boston, Massachusetts 02109 Telephone: (617) 526-6000 |
Jennifer Elliott, Ph.D., Esq. Chief Legal Officer Generation Bio Co. 301 Binney Street Cambridge, MA 02142 (617) 655-7500 |
Deanna Kirkpatrick, Esq. Yasin Keshvargar, Esq. Davis Polk & Wardwell LLP 450 Lexington Avenue New York, NY 10017 (212) 450-4000 |
Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement is declared effective.
If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☐
If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ 333-238608
If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☐ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
| ||||||||
Title of Each Class of Securities to Be Registered |
Amount to be Registered (1) |
Proposed Maximum Offering Price Per Share (2) |
Proposed Maximum Aggregate Offering Price (2) |
Amount of Registration Fee | ||||
Common Stock, $0.0001 par value per share |
605,263 shares | $19.00 | $11,499,997 | $1,493 | ||||
| ||||||||
|
(1) | Includes 78,947 shares of common stock the underwriters have the option to purchase. |
(2) | Calculated pursuant to Rule 457(a) under the Securities Act of 1933, as amended, based on the initial public offering price. |
EXPLANATORY NOTE AND INCORPORATION BY REFERENCE
This registration statement is being filed with respect to the registration of additional shares of common stock, par value $0.0001 per share, of Generation Bio Co., a Delaware corporation, pursuant to Rule 462(b) under the Securities Act of 1933, as amended. The contents of the earlier registration statement on Form S-1 (File No. 333-238608), which was declared effective by the Securities and Exchange Commission on June 11, 2020, are incorporated in this registration statement by reference.
The required opinions and consents are listed on an Exhibit Index attached hereto and filed herewith.
EXHIBIT INDEX
.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on this 11th day of June, 2020.
GENERATION BIO CO. | ||||
By: | ||||
/s/ Geoff McDonough |
||||
Geoff McDonough, M.D. President and Chief Executive Officer |
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date | ||
/s/ Geoff McDonough Geoff McDonough, M.D. |
President, Chief Executive Officer and Director (principal executive officer) | June 11, 2020 | ||
/s/ Stephen DiPalma Stephen DiPalma |
Interim Chief Financial Officer (principal financial officer) | June 11, 2020 | ||
* Catherine Stehman-Breen, M.D. |
Director | June 11, 2020 | ||
* Gustav Christensen |
Director | June 11, 2020 | ||
* Jeffrey Jonas, M.D. |
Director | June 11, 2020 | ||
* Donald Nicholson, Ph.D. |
Director | June 11, 2020 | ||
* Jason Rhodes |
Director | June 11, 2020 | ||
* Charles Rowland |
Director | June 11, 2020 | ||
* Anthony Quinn, M.B. Ch.B., Ph.D. |
Director | June 11, 2020 |
*By: | /s/ Geoff McDonough | |
Geoff McDonough, M.D. | ||
Attorney-in-fact |